文献速递淋巴瘤

无症状早期慢性淋巴细胞白血病的国际预后评分

International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia.
PubMed 文献 · Blood · 2020-01-01

研究基于11个国际队列共4933例早期无症状慢性淋巴细胞白血病(CLL)患者的个体数据,构建并验证了预测至首次治疗时间(TTFT)的国际预后评分IPS-E。该评分由IGHV未突变、绝对淋巴细胞计数>15×10^9/L和可触及淋巴结三项各计1分组成,将患者分为低危(0分)、中危(1分)和高危(2-3分),三组5年累积治疗风险分别为8.4%、28.4%和61.2%。

要点

  • IPS-E评分包含IGHV未突变、淋巴细胞>15×10^9/L和可触及淋巴结三项,各计1分。
  • 评分将患者分为低危(0分)、中危(1分)、高危(2-3分),5年治疗风险分别为8.4%、28.4%、61.2%。
  • 该模型简单稳健,可用于临床管理及早期干预试验设计。

核心结论

  • IPS-E是预测早期无症状CLL患者治疗需求的简单稳健预后模型。

研究设计与样本

  • 研究分析11个国际队列共4933例早期CLL患者的个体数据以构建和验证预后评分。

主要发现

  • IGHV未突变、绝对淋巴细胞计数>15×10^9/L和可触及淋巴结与TTFT独立相关。
  • IPS-E评分将患者分为低危(0分)、中危(1分)、高危(2-3分),三组TTFT显著不同。
  • 训练集C-index为0.74,验证集汇总C-index为0.70。
  • 训练与验证队列荟萃分析显示,低、中、高危组5年累积治疗启动风险分别为8.4%、28.4%、61.2%。

关键数值与推荐

  • IPS-E评分:IGHV未突变计1分,绝对淋巴细胞计数>15×10^9/L计1分,可触及淋巴结计1分。
  • 风险分层:低危0分,中危1分,高危2-3分。
  • 5年累积治疗启动风险:低危8.4%,中危28.4%,高危61.2%。

临床怎么用

  • IPS-E可用于早期无症状CLL患者的临床管理,帮助预测治疗需求。
  • 该评分可用于设计早期干预临床试验的患者分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Most patients with chronic lymphocytic leukemia (CLL) are diagnosed with early-stage disease and managed with active surveillance. The individual course of patients with early-stage CLL is heterogeneous, and their probability of needing treatment is hardly anticipated at diagnosis. We aimed at developing an international prognostic score to predict time to first treatment (TTFT) in patients with CLL with early, asymptomatic disease (International Prognostic Score for Early-stage CLL [IPS-E]). Individual patient data from 11 international cohorts of patients with early-stage CLL (n = 4933) were analyzed to build and validate the prognostic score. Three covariates were consistently and independently correlated with TTFT: unmutated immunoglobulin heavy variable gene (IGHV), absolute lymphocyte count higher than 15 × 109/L, and presence of palpable lymph nodes. The IPS-E was the sum of the covariates (1 point each), and separated low-risk (score 0), intermediate-risk (score 1), and high-risk (score 2-3) patients showing a distinct TTFT. The score accuracy was validated in 9 cohorts staged by the Binet system and 1 cohort staged by the Rai system. The C-index was 0.74 in the training series and 0.70 in the aggregate of validation series. By meta-analysis of the training and validation cohorts, the 5-year cumulative risk for treatment start was 8.4%, 28.4%, and 61.2% among low-risk, intermediate-risk, and high-risk patients, respectively. The IPS-E is a simple and robust prognostic model that predicts the likelihood of treatment requirement in patients with early-stage CLL. The IPS-E can be useful in clinical management and in the design of early intervention clinical trials.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Condoluci A, Terzi di Bergamo L, Langerbeins P, et al. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood. 2020. PMID: 32267500. doi:10.1182/blood.2019003453

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。